Artur Martins Coutinho

List of Publications by Year
in descending order

33 papers	552 citations	623734 14 h-index	642732 23 g-index
35 all docs	35 docs citations	35 times ranked	1057 citing authors

#	Article	IF	Citations
1	Imaging Aspects of the Hippocampus. Radiographics, 2022, 42, 822-840.	3.3	4
2	The Association Between Acquired Color Deficiency and PET Imaging of Neurodegeneration in Mild Cognitive Impairment and Alzheimer Disease. , 2022, 63, 20.		1
3	<scp>FDGâ€PET</scp> Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome. Movement Disorders, 2021, 36, 651-661.	3.9	22
4	Footâ€Hand Synkinesis in Corticobasal Syndrome: Single Clinical Feature with Distinct Molecular Imaging Biomarkers. Movement Disorders Clinical Practice, 2021, 8, 491-492.	1.5	2
5	General Concepts in Theranostics. PET Clinics, 2021, 16, 313-326.	3.0	10
6	The Brain Metabolic Signature in Superagers Using In Vivo ^{1}H-MRS: A Pilot Study. American Journal of Neuroradiology, 2021, 42, 1790-1797.	2.4	2
7	Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimerâ€™s disease continuum. Brain and Cognition, 2021, 152, 105749.	1.8	9
8	Metabolic and Structural Signatures of Speech and Language Impairment in Corticobasal Syndrome: A Multimodal PET/MRI Study. Frontiers in Neurology, 2021, 12, 702052.	2.4	10
9	Subjective sleep parameters in prodromal Alzheimerâ€™s disease: a case-control study. Revista Brasileira De Psiquiatria, 2021, 43, 510-513.	1.7	6
10	Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects. Journal of Alzheimer's Disease, 2020, 78, 229-244.	2.6	5
11	<i>In vivo</i> imaging evidence of poor cognitive resilience to Alzheimer's disease pathology in subjects with very low cognitive reserve from a lowâ€middle income environment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12122.	2.4	4
12	Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2666-2680.	6.4	21
13	Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics, 2020, 40, 1715-1740.	3.3	65
14	Topography of 11C-Pittsburgh compound B uptake in Alzheimerâ€™s disease: a voxel-based investigation of cortical and white matter regions. Revista Brasileira De Psiquiatria, 2019, 41, 101-111.	1.7	18
15	[18F]FDG-PET in a case of right temporal lobe variant of frontotemporal dementia. Dementia E Neuropsychologia, 2019, 13, 350-351.	0.8	2
16	Brain [18F]FDG PET-CT imaging in posterior cortical atrophy. Arquivos De Neuro-Psiquiatria, 2019, 77, 752-753.	0.8	0
17	Effects of Subthalamic Stimulation on Olfactory Function in Parkinson Disease. World Neurosurgery, 2018, 114, e559-e564.	1.3	15
18	Aerobic training modulates salience network and default mode network metabolism in subjects with mild cognitive impairment. NeuroImage: Clinical, 2018, 19, 616-624.	2.7	6

#	Article	IF	Citations
19	Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdominal Radiology, 2017, 42, 1141-1151.	2.1	52
20	Differential associations between systemic markers of disease and cortical thickness in healthy middle-aged and older adults. NeuroImage, 2017, 146, 19-27.	4.2	12
21	Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. Nuclear Medicine Communications, 2016, 37, 1095-1101.	1.1	15
22	Teaching Neuro <i>Images</i> : Mills syndrome. Neurology, 2016, 87, e54.	1.1	2
23	Positron Emission Tomography with 18F-Fluorodeoxyglucose Imaging Patterns in Autoimmune Encephalitis. Current Radiology Reports, 2016, 4, 1.	1.4	0
24	18F-FDG PET/CT Osteometabolic Activity in Metastatic Parathyroid Carcinoma. Clinical Nuclear Medicine, 2016, 41, 724-725.	1.3	5
25	Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects. Alzheimer's Research and Therapy, 2015, 7, 58.	6.2	29
26	Analysis of the posterior cingulate cortex with [18 F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer's disease: Correlations and differences between the two methods. Dementia E Neuropsychologia, 2015, 9, 385-393.	0.8	12
27	Effects of Duodenal-Jejunal Bypass Liner (EndoBarrier®) on Gastric Emptying in Obese and Type 2 Diabetic Patients. Obesity Surgery, 2015, 25, 1618-1625.	2.1	39
28	Effects of Aerobic Training on Cognition and Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 46, 747-760.	2.6	24
29	Changes in Neuropsychological Tests and Brain Metabolism After Bariatric Surgery. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2347-E2352.	3.6	47
30	Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2014, 55, 1936-1944.	5.0	63
31	Paraneoplastic limbic encephalitis with prominent neuropsychiatric apathy. Journal of the Neurological Sciences, 2014, 337, 224-227.	0.6	1
32	Long-Term Lithium Treatment Reduces Glucose Metabolism in the Cerebellum and Hippocampus of Nondemented Older Adults: An [¹⁸F]FDG-PET Study. ACS Chemical Neuroscience, 2014, 5, 484-489.	3.5	19
33	Consistency of FDG-PET Accuracy and Cost-Effectiveness in Initial Staging of Patients With Hodgkin Lymphoma Across Jurisdictions. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 314-320.	0.4	22